Literature DB >> 18234802

Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells.

Meichi Hsu1, Shih-Yi Wu, Shih-Shin Chang, Ih-Jen Su, Ching-Hwa Tsai, Siao-Jing Lai, Ai-Li Shiau, Kenzo Takada, Yao Chang.   

Abstract

Epstein-Barr virus (EBV)-associated, undifferentiated type of nasopharyngeal carcinoma (NPC) is characterized by intensive leukocyte infiltration. Interaction between the infiltrating cells and the tumor cells has been considered crucial for NPC development. Recruitment of the infiltrates can be directed by certain chemokines present in the NPC tissues. It is unknown whether and how EBV lytic infection regulates expression of the chemokines. Using an antibody array, we first found that several chemokines secreted from EBV-infected NPC cells are increased upon EBV reactivation into the lytic cycle, and interleukin-8 (IL-8) is the chemokine upregulated most significantly and consistently. Further studies showed that the EBV lytic transactivator Zta is a potent inducer of IL-8 in NPC cells, augmenting secreted and intracellular IL-8 proteins, as well as IL-8 RNA. Zta upregulates Egr-1, a cellular transcription factor that has been involved in upregulation of IL-8, but the Zta-induced IL-8 expression is independent of Egr-1. The ability of Zta to transactivate the IL-8 promoter is important for the induction of IL-8, and we have identified two Zta-responsive elements in the promoter. Zta can bind to these two elements in vitro and can also be recruited to the IL-8 promoter in vivo. DNA-binding-defective Zta mutants can neither activate the IL-8 promoter nor induce IL-8 production. In addition, Zta-expressing NPC cells exert enhanced chemotactic activity that is mainly mediated by IL-8. Since IL-8 may contribute to not only leukocyte infiltration but also multiple oncogenic processes, the present study provides a potential link between EBV lytic infection and pathogenesis of NPC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18234802      PMCID: PMC2268478          DOI: 10.1128/JVI.02301-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Characterization of the Epstein-Barr virus BZLF1 protein transactivation domain.

Authors:  E K Flemington; A M Borras; J P Lytle; S H Speck
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies.

Authors:  D Martel-Renoir; V Grunewald; R Touitou; G Schwaab; I Joab
Journal:  J Gen Virol       Date:  1995-06       Impact factor: 3.891

3.  Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1.

Authors:  E B Quinlivan; E A Holley-Guthrie; M Norris; D Gutsch; S L Bachenheimer; S C Kenney
Journal:  Nucleic Acids Res       Date:  1993-07-11       Impact factor: 16.971

Review 4.  Inflammation, a key event in cancer development.

Authors:  Haitian Lu; Weiming Ouyang; Chuanshu Huang
Journal:  Mol Cancer Res       Date:  2006-04       Impact factor: 5.852

5.  Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells.

Authors:  L Xu; I J Fidler
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

6.  DNA-binding-defective mutants of the Epstein-Barr virus lytic switch activator Zta transactivate with altered specificities.

Authors:  E K Flemington; J P Lytle; C Cayrol; A M Borras; S H Speck
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

Review 7.  Neutrophil activation and the effects of interleukin-8/neutrophil-activating peptide 1 (IL-8/NAP-1).

Authors:  M Baggiolini; P Imboden; P Detmers
Journal:  Cytokines       Date:  1992

8.  Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells.

Authors:  C Cochet; D Martel-Renoir; V Grunewald; J Bosq; G Cochet; G Schwaab; J F Bernaudin; I Joab
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

9.  IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor.

Authors:  D Schadendorf; A Möller; B Algermissen; M Worm; M Sticherling; B M Czarnetzki
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

10.  Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes.

Authors:  A Chuntharapai; J Lee; C A Hébert; K J Kim
Journal:  J Immunol       Date:  1994-12-15       Impact factor: 5.422

View more
  32 in total

1.  Modulation of lung inflammation by the Epstein-Barr virus protein Zta.

Authors:  James F Guenther; Jennifer E Cameron; Hong T Nguyen; Yu Wang; Deborah E Sullivan; Bin Shan; Joseph A Lasky; Erik K Flemington; Gilbert F Morris
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-09-03       Impact factor: 5.464

2.  Epstein-Barr virus deubiquitinase downregulates TRAF6-mediated NF-κB signaling during productive replication.

Authors:  Shinichi Saito; Takayuki Murata; Teru Kanda; Hiroki Isomura; Yohei Narita; Atsuko Sugimoto; Daisuke Kawashima; Tatsuya Tsurumi
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

3.  Expression of CXCR1 (interleukin-8 receptor) in murine macrophages after staphylococcus aureus infection and its possible implication on intracellular survival correlating with cytokines and bacterial anti-oxidant enzymes.

Authors:  Biswadev Bishayi; Debasish Bandyopadhyay; Arnab Majhi; Rana Adhikary
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

4.  The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins.

Authors:  Jillian A Bristol; Amanda R Robinson; Elizabeth A Barlow; Shannon C Kenney
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

5.  A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.

Authors:  Shi-Dong Ma; Subramanya Hegde; Ken H Young; Ruth Sullivan; Deepika Rajesh; Ying Zhou; Ewa Jankowska-Gan; William J Burlingham; Xiaoping Sun; Margaret L Gulley; Weihua Tang; Jenny E Gumperz; Shannon C Kenney
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

6.  Photodynamic therapy-mediated modulation of inflammatory cytokine production by Epstein-Barr virus-infected nasopharyngeal carcinoma cells.

Authors:  Ho-Kee Koon; Kwok-Wai Lo; Kwok-Nam Leung; Maria Li Lung; Chris Chi-Kwong Chang; Ricky Ngok-Shun Wong; Wing-Nang Leung; Nai-Ki Mak
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

7.  Initiation of lytic DNA replication in Epstein-Barr virus: search for a common family mechanism.

Authors:  Andrew J Rennekamp; Paul M Lieberman
Journal:  Future Virol       Date:  2010-01       Impact factor: 1.831

8.  Evaluation of a prediction protocol to identify potential targets of epigenetic reprogramming by the cancer associated Epstein Barr virus.

Authors:  Kirsty Flower; Elizabeth Hellen; Melanie J Newport; Susan Jones; Alison J Sinclair
Journal:  PLoS One       Date:  2010-02-26       Impact factor: 3.240

Review 9.  The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Authors:  A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

10.  Specific NFkappaB subunit activation and kinetics of cytokine induction in adenoviral keratitis.

Authors:  Jaya Rajaiya; Neda Sadeghi; James Chodosh
Journal:  Mol Vis       Date:  2009-12-25       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.